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Abstract
Background: Colorectal cancer (CRC) is a common and important disease. There are different tests for diagnosis,
one of which is computed tomographic colonography (CTC). No test is perfect, and patients with normal CTC may
subsequently develop CRC (either because it was overlooked originally, or because it has developed in the interim).
This is termed post-investigation colorectal cancer (PICRC) or “interval cancer”. How frequently this occurs after CTC
is not known. The purpose of this systematic review and meta-analysis is to use the primary literature to estimate
the PICRC rate after CTC, and explore associated factors.
Methods: Primary studies reporting post-investigation colorectal cancer (PICRC) rates after CTC will be identified
from PubMed, Embase and Cochrane Register of Controlled Trials databases. Peer-reviewed studies published after
1994 (the year CTC was introduced) will be included and the rate of PICRC within 36 months of CTC recorded. Data
will be extracted from selected studies for a random effects meta-analysis. Heterogeneity, risk of bias and
publication bias will be assessed, and exploratory analysis will examine factors associated with higher PICRC rates in
the literature.
Conclusion: PICRC rates are the ultimate benchmark of diagnostic quality for colonic investigations. This systematic
review and meta-analysis will identify and synthesise evidence to determine PICRC rates after CTC and explore
factors that may contribute to higher rates.
Systematic review registration: PROSPERO (registration number CRD42016042437).
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Background
Rationale
Colorectal cancer (CRC) is a common disease with high
morbidity, mortality and healthcare costs, affecting over
half a million people each year globally [1], ultimately
proving fatal in approximately 50% of cases. Early dis-
ease has an excellent prognosis, whereas diagnosis at a
late stage carries much higher mortality [2], indicating
the importance of having rapid, easily accessible and
highly sensitive diagnostic tests that are acceptable to
patients. Diagnosis of CRC at an early, readily-treatable
stage (for example, by population screening) has been
proven by meta-analysis of several randomised trials to
reduce disease-specific mortality [3]. However, this is
not the only benefit of CRC screening. The prevailing
hypothesis of colorectal carcinogenesis postulates that
most CRC develop from potentially premalignant pre-
cursor polyps; either adenomas (the so-called adenoma-
* Correspondence: andrew.plumb@nhs.net
1Centre for Medical Imaging, University College London, 3rd Floor East, 250
Euston Rd, London, NW NW1 2PG, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Plumb et al. Systematic Reviews  (2017) 6:36 
DOI 10.1186/s13643-017-0432-8
carcinoma hypothesis [4]) or serrated lesions (the “ser-
rated pathway” [5]). In support, removal of adenomas
via endoscopic polypectomy reduces the incidence of
subsequent CRC [6], proving beyond reasonable doubt
that a proportion of adenomas are destined to transform
into malignant CRC. Therefore, timely investigation of
the colon improves CRC outcomes in two broad ways—-
firstly, early detection of established CRC improves
disease-specific mortality [3]; and secondly, identification
and removal of CRC precursors reduces disease inci-
dence [6].
The most common tests for investigation of the whole
colon (as opposed to just the more distal portion) are
optical colonoscopy (OC) and computed tomographic
colonography (CTC). OC uses a small video camera
mounted on a flexible tube that can be navigated around
the entire colon to identify abnormalities, including CRC
and polyps [7]. Furthermore, OC permits simultaneous
polyp removal (polypectomy) using instruments that can
be delivered down the colonoscope channel. CTC relies
on rapid, high-resolution CT scanning of the prepared,
gas-distended colon. Polyps and cancers are depicted by
their disruption of the normal smooth wall of the colon
or by ancillary features such as wall thickening [8].
The diagnostic accuracy of CTC has been studied ex-
tensively, with meta-analysis suggesting that diagnostic
sensitivity for established CRC is equal to that of OC [9].
However, CTC is less sensitive than OC for small (6–
9 mm) and diminutive (0–5 mm) polyps, with one meta-
analysis suggesting approximately 70% sensitivity for 6–
9 mm lesions [10]. In the majority of cases, this is of no
clinical consequence because the large majority of small
and diminutive polyps rarely harbour high-risk premalig-
nant features or invasive CRC [11]. However, the precise
risk is unknown for any given individual. Therefore, it is
possible that the rates of post-investigation CRC
(PICRC) after CTC are greater than after colonoscopy
because of the small but non-zero risk of a small or di-
minutive polyp transitioning to invasive CRC. Although
PICRC rates after colonoscopy have been reported
widely [12–16], and been the subject of systematic re-
view [17], this is not true for CTC. This hampers physi-
cians’ and policy-makers’ ability to provide evidence-
based recommendations regarding suitable follow-up in-
tervals after a negative CTC examination.
Here, we report the protocol for a systematic re-
view (SR) and meta-analysis of PICRC rates after
negative CTC.
Objectives
The present study will systematically review and, if pos-
sible, meta-analyse the available literature reporting
PICRC rate following CTC. We wish to estimate the
prevalence of PICRC in patients undergoing CTC, the
uncertainty surrounding this estimate and explore po-
tential explanatory factors associated with higher PICRC
rates. Since PICRC may occur at variable times after an
index text, we will examine several time horizons, ran-
ging from 1 to 5 years after CTC. We will also assess
and document the quality of the available literature, and,
if necessary, make recommendations for future research
and study reporting. This protocol is registered with
PROSPERO (CRD42016042437) and has been reported
in accordance with the PRISMA-P guidelines (see Add-
itional file 1—PRISMA-P checklist) [18].
Methods
Eligibility criteria
Studies will be selected according to the criteria below.
Study design and participants
We will include randomised controlled trials (RCTs), co-
hort, cross-sectional and case-control studies reporting
original data for in vivo research in adult human partici-
pants, and reporting a PICRC rate (or sufficient data for
such a rate to be calculated, see definitions below). Stud-
ies will be grouped together to calculate the PICRC ra-
ther than treating them separately. We will restrict our
search to peer-reviewed, full-research reports. Studies in
which the CTC examination was conducted immediately
following colonoscopic diagnosis of CRC (e.g. to
complete colonic imaging upstream of a stenosing co-
lonic tumour, “completion CTC”) will be excluded, un-
less these patients constituted less than 50% of the
imaged population or were presented as a separately
identifiable subset that can be excluded during data ex-
traction. We will examine the effect of including studies
with such high rates of completion CTC on the esti-
mated PICRC rate by conducting a sensitivity analysis,
in which we will re-calculate this rate after excluding
studies with prevalences of completion CTC from 0 to
50% in 10% increments.
CTC test methods
We will define CTC as CT scanning of the prepared,
gas-distended colon. Only studies in which CTC was
conducted with at least dual patient positioning, gas dis-
tension and either bowel cleansing or faecal tagging will
be included. We will not stipulate a particular mode of
interpretation of CTC (e.g. two-dimensional vs three-
dimensional) since both are used in clinical practice.
Definition and identification of CTC-detected cancers and
PICRC
We will define a CTC-detected cancer as having oc-
curred if either (1) direct inspection of radiology reports
permitted the study authors to determine that CTC di-
agnosed a CRC or (2) CRC was diagnosed within
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6 months of CTC occurring, and the CTC report was
not available for review (in common with the OC litera-
ture, in which CRC diagnosed within 6 months of an
index OC are assumed to have been detected by that test
[12–16]), whereas diagnoses after that period are as-
sumed to be PICRC. We will record which of these pos-
sibilities applies to each included study and report
outcomes for these two groups of studies separately. We
anticipate that studies from group (1) will be RCTs or
smaller observational series, in which CTC reports are
freely available to investigators, and studies from group
(2) will be larger-scale population-based studies using
database linkage methods in which full CTC reports
may not be available.
A PICRC will be defined as diagnosis of CRC within
5 years of CTC that did not detect a cancer (i.e. did not
meet either criterion 1 or 2 above). Recurrent CRC after
a positive initial CTC will therefore not be regarded as
PICRC. We will require studies to report a minimum
period of 12 months follow-up after CTC, since shorter
follow-up periods are likely to miss a substantial propor-
tion of PICRC (which may not reach medical attention
until beyond this time period). PICRC must be identified
by reference to a cancer registry or intelligence network
that is at least regional in scope (i.e. encompassing mul-
tiple hospitals from beyond a single municipal area), or
with each individual’s true disease status determined at
follow-up by a dedicated whole-colon examination (ei-
ther colonoscopy, repeat CTC or colon capsule). If pa-
tients do not undergo a definitive follow-up
examination, identification of PICRC solely by searching
local cancer databases, registries or multidisciplinary
team meeting records will not be acceptable, as PICRC
could be detected at institutions remote from those con-
ducting the index CTC. We will record the nature and
scope of the registry by which PICRC cases are identified
for each individual research study.
Setting and language
There will be no restriction by study setting. We will in-
clude reports in English, French, Spanish and German,
arranging for translation where necessary. We will pro-
vide a list of potentially eligible articles from other lan-
guages in an appendix.
Information sources
We will use the Ovid SP interface to search MEDLINE
and Embase, and the Wiley interface to search the
Cochrane Register of Controlled Trials, from 1994 on-
wards (the year that CTC was first described [19, 20]).
We will also scan the reference list of included studies
and any relevant narrative reviews identified by the
search. Finally, we will compare the list generated by the
search with studies already known to the investigators.
Search strategy
The search strategy has been devised in conjunction be-
tween the study investigators, an information scientist
and other experts in the field of CTC and imaging re-
search. We will use a combination of medical subject
headings (MeSH) and free-text terms relating to CTC
and colorectal cancer. For CTC, the MeSH terms will
be: “Colonography, Computed Tomographic”, which has
replaced the previous terms “CT Colonography”; “Colo-
nography, CT”; “Colonoscopy, Virtual”; “Computed
Tomographic Colonography”; and “Virtual Colonos-
copy”. A preliminary search has revealed no incremental
benefit from including the older MeSH terms. The free-
text terms will be ((CT or (comput* and tomogra*) and
colonogra*) or (virtua* and colonosc*)). These will be
combined using the “OR” operator, to return articles re-
lating to CTC. Subsequently, we will search for articles
regarding colorectal cancer by using the MeSH term
“Colorectal Neoplasms”, combined with the free-text
terms “colorectal” and “cancer” using the “OR” operator.
Finally, we will combine the two searches (i.e. colorectal
cancer and CTC) as below:
1. ((CT or (comput* and tomogra*)) and colonogra*).af
2. (virtua* and colono*).af
3. 1 or 2
4. colonography, computed tomographic.sh
5. 3 or 4
6. 5 and Journal Article.pt
7. ((colon or colorect*) and (cancer or carcinoma)).af
8. colorectal neoplasms.sh
9. 7 or 8
10.9 and Journal Article.pt
11.6 and 10
We will use the Ovid SP interface “Filters” options to
restrict to articles reporting human research published
after 1994.
Selection process
Two independent review authors will screen all titles
and abstracts of the articles identified by the search de-
scribed above against the eligibility criteria. We will ob-
tain the full text article for all reports that then appear
to meet our criteria, or where there is uncertainty. If
there is persistent uncertainty after reviewing the full
text reports, we will attempt to contact the correspond-
ing author of the study in question. Disagreement will
be resolved by discussion between co-authors, and we
will record the reasons for excluding each individual
study identified by the search string. The number of arti-
cles included and excluded at each stage of the selection
process will be summarised using a flowchart. We will
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report the level of inter-rater agreement between the au-
thors performing such selection.
Data management and extraction process
The results of the search above will be retrieved to an
Endnote ×7 (Thomson Reuters, Toronto, ON, Canada)
database that will be shared between the reviewers using
the online interface. Subsequently, each reviewer will ex-
port potentially eligible abstracts to a new Endnote li-
brary. These will be combined and full text articles
retrieved, thereby facilitating subsequent full text article
screening. We will use the de-duplication functions of
Ovid SP at the search stage and of Endnote ×7 at the
article screening stage.
Once the final set of eligible articles has been identi-
fied, we will extract relevant data (detailed below) from
each article into a Microsoft Excel 2016 spreadsheet de-
signed specifically for the review (see Additional file
2—Extraction sheet). All articles will be extracted by two
authors working independently and after extracting data
from 10 articles, the agreement between the two authors
will assessed. If agreement is lower than 80%, we will re-
tain dual independent extraction. All differences will be
resolved by discussion between the disagreeing parties,
with a third senior author arbitrating where necessary.
We will contact corresponding authors for articles in
which data items necessary to inform the primary out-
come are not available from the full text reports. Dupli-
cate reports of the same patient data set (i.e. duplicate,
overlapping or companion studies) will be combined
and extracted as a single study. If there are logical incon-
sistencies between these duplicate reports, or if overlap-
ping data cannot be separated into extractable
constituents, we will contact the corresponding author(s)
of the article in question for clarification and exclude
the article if no response is received within 30 days.
Data items
We will extract the following: (a) study characteristic-
s—primary author, year of publication, period of patient
recruitment/inclusion, geographical location of the
population studied, study design and number of centres
involved, length of follow-up to permit post-CTC can-
cers to be identified; (b) patient characteristics—number
of patients included, reason for undergoing CTC, gender
distribution and age distribution; (c) CTC test character-
istics—number of CTC examinations conducted, num-
ber completed successfully, number analysed, mode of
bowel preparation, use of faecal tagging, CT scanner
type (multi- vs single-row detector row), exposure fac-
tors of kVp and mAs, reconstruction interval and use of
intravenous contrast; (d) radiologist/reader characteris-
tics—predominant mode of interpretation (i.e. primary
two-dimensional, primary three-dimensional or mixed)
and reader training and experience; (e) tumour charac-
teristics—number of patients with CRC detected by
CTC (see definition above for detected CRC), number of
patients with CRC not detected by CTC (i.e. PICRC, see
definition above), location (proximal vs distal) of de-
tected and missed cancers, temporal interval between
the index CTC and the diagnosis of PICRC, and whether
or not the PICRC was visible in retrospect on the CTC
images.
Outcomes
The primary outcome will be the prevalence of PICRC
at 36 months follow-up after CTC, since this is the time
horizon most commonly reported in the OC literature
[12–16]. This will be expressed as the proportion of
PICRC from the total of cancers detected (i.e. using the
number of CRC as the denominator) and, secondarily, as
the proportion of CTC examinations leading to a PICRC
(i.e. using number of CTC examinations as the denom-
inator). The latter figure is subject to variation as a re-
sult of lesion prevalence but may be more representative
of what may be expected in routine clinical practice. By
analogy with sensitivity for a diagnostic test, the total
number of CRC will include those detected by both the
index test and by subsequent follow-up (i.e. “disease
positive”). If studies do not report data for 36 months
follow-up, we will nonetheless extract the date for the
closest timepoint to 36 months that is reported. Sec-
ondary outcomes will be the prevalence of PICRC at
5 years (60 months) follow-up (i.e. the current recom-
mended screening interval for CTC [21]); incidence of
PICRC per 1000 person-years of follow-up; the ana-
tomical distribution (i.e. proximal vs distal colon) of
detected CRC and PICRC; CTC scan technique, radi-
ologist and patient characteristics associated with
higher rates of PICRC; the proportion of PICRC that
were visible on the images in retrospect (and poten-
tial reasons for these being missed initially) and lit-
erature quality (see subsequent section).
Quality assessment and risk of bias of individual studies
We will assess the quality of included studies using a
pre-specified quality assessment tool (), adapted from
the Newcastle-Ottawa Scale (NOS) for non-randomised
studies (see Additional file 3—Modified NOS) [22]. We
do not anticipate assigning studies an overall quality
score by pooling individual elements, as this may be un-
reliable [18]. We will report the overall components of
the quality assessment for each study graphically using
the “star rating” system of the NOS. Studies with no
stars for any of the individual components of the NOS
(selection, comparability and outcome assessment) will
not be included in the quantitative synthesis.
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Data synthesis
If the studies are sufficiently homogenous in their de-
sign, outcome assessment and follow-up, we will con-
duct meta-analyses using a random effects model
(DerSimonian and Laird [23]) using the current version
of R (R Foundation for statistical computing, Vienna,
Austria) [24]. We will use the relatively more conserva-
tive random effects model as we expect studies to have
included a variety of patient participants (e.g. screening
and symptomatic populations) and use radiologists of
varying expertise. We will combine the percentage of pa-
tients with PICRC in each individual study to estimate a
pooled prevalence, along with a 95% confidence interval
(CI). If studies report variable lengths of follow-up pre-
venting meta-analysis of prevalence at a 36-month time
point, we will attempt to estimate a survival curve for
PICRC from the individual study estimates using ran-
dom effects survival meta-analysis [25]. If available, we
will compare the prevalence of proximal and distal
PICRC using an odds ratio (OR) with 95%CI. We will
assess heterogeneity between study-specific estimates
using the inconsistency index (I2 statistic [26]). If hetero-
geneity is considerable (I2 > 75%) and the p value <0.1,
we will not perform quantitative data synthesis [18]. We
will investigate between-study sources of heterogeneity
using subgroup analyses by stratifying original estimates
according to study characteristics, CTC technique and
radiologist factors as described in the data extraction
section above. We plan to investigate for small study ef-
fects (and possible publication bias) both qualitatively,
by inspecting funnel plots [27], and quantitatively, using
the test proposed by Harbord [28], although we will
defer a decision regarding the suitability of these
methods until the number of included studies and
between-study heterogeneity is known. If there is evi-
dence of possible publication bias and heterogeneity is
sufficiently low (I2 < 25%) [26], we will estimate PICRC
rates using the trim and fill method [29] to gain an ap-
proximation of the “missing” study rates and overall
summary estimate and will present this as an estimate of
the potential impact of missing studies.
Confidence in cumulative estimate
The strength of the overall weight of evidence for the
primary outcome will be judged using the Grading of
Recommendations Assessment, Development and Evalu-
ation (GRADE) working group methodology [30]. This
will encompass the key domains of risk of bias,
consistency, directness, precision and publication bias,
and will incorporate the quality assessments of individ-
ual studies and estimates of publication bias described
above (see above). We will consider all articles that are
selected for the systematic review, even if they are ex-
cluded from the quantitative meta-analysis. The overall
research literature quality will be summarised as high
(we are very confident that the true PICRC rate lies close
to the estimate presented), moderate (we are moderately
confident in the PICRC rate presented), low (we have
limited confidence in the estimated PICRC rate) or very
low (we have very little confidence in the calculated
PICRC rate, i.e. the true PICRC rate is likely to be sub-
stantially different), in accordance with GRADE
recommendations.
Discussion
CTC is a widely available and commonly-used diag-
nostic test, with over 80,000 examinations performed
each year in England alone [31] (predicted to rise to
150,000 per year by 2020 [32]). Although diagnostic
accuracy has been estimated by prior meta-analysis
[9, 10, 33–35], the longer-term effect of the test’s
relatively lower sensitivity for small colorectal polyps
(vs. the main competing technology, colonoscopy) is
not known. It is plausible that this translates to
higher rates of PICRC than colonoscopy. Conversely,
the opposite is also possible—for example, if incom-
plete colonic evaluation was commoner at colonos-
copy than CTC, then this might translate to higher
PICRC rates. The technical failure rate of CTC is ex-
tremely low in routine clinical practice (at around
0.7–2.0% [36, 37]), meaning this scenario is at least
possible. For example, in a randomised study compar-
ing CTC and colonoscopy in symptomatic patients,
the rate of clinical uncertainty/inadequate examinations
after CTC was half that of colonoscopy [38]. This system-
atic review will permit an estimate of the prevalence of
PICRC and explore factors that may contribute to missed
lesions. Predetermined measures of study quality and pub-
lication bias will be used to describe the confidence in the
published literature. Possible limitations to the execu-
tion of this systematic review include limited primary
literature with incomplete reporting, precluding ability
to extract the necessary data. However, we anticipate
that the review will be of value in planning quality
markers for CTC and in designing rationalised follow-
up and repeat imaging schedules for patients with a
negative initial CTC examination.
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